RT Journal Article
T1 External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.
A1 Jimenez-Fonseca, Paula
A1 Carmona-Bayonas, Alberto
A1 Martinez-Torron, Alba
A1 Alsina, Maria
A1 Custodio, Ana
A1 Serra, Olbia
A1 Cacho Lavin, Diego
A1 Limón, María Luisa
A1 Sauri, Tamara
A1 López, Flora
A1 Visa, Laura
A1 Granja, Mónica
A1 Martínez Lago, Nieves
A1 Arrazubi, Virginia
A1 Vidal Tocino, Rosario
A1 Hernandez, Raquel
A1 Aguado, Gema
A1 Cano, Juana María
A1 Martín Carnicero, Alfonso
A1 Mangas, Monserrat
A1 Pimentel, Paola
A1 Fernández Montes, Ana
A1 Macias Declara, Ismael
A1 Longo, Federico
A1 Ramchandani, Avinash
A1 Martín Richard, Marta
A1 Hurtado, Alicia
A1 Azkarate, Aitor
A1 Hernández Pérez, Carolina
A1 Serrano, Raquel
A1 Gallego, Javier
A1 AGAMENON-SEOM study group, 
K1 HER2
K1 chemotherapy
K1 external validity
K1 gastric cancer
K1 oxaliplatin
K1 trastuzumab
AB Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cancer patients based on the ToGA trial. Despite the lack of phase III trials, many clinicians administer trastuzumab with alternative regimens. One meta-analysis suggests that substituting cisplatin for oxaliplatin might lead to greater efficacy and less toxicity. 594 patients with HER2-positive gastroesophageal adenocarcinoma were recruited from the AGAMENON-SEOM registry. The objective was to evaluate the external validity of clinical trials with chemotherapy and trastuzumab. The regimens used in at least 5% of the patients were XP (27%), oxaliplatin and capecitabine (CAPOX) (26%), oxaliplatin and 5-fluorouracil (FOLFOX) (14%), FP (14%), triplet with anthracycline/docetaxel (7%), and carboplatin-FU (5%). Median exposure to trastuzumab was longer with FOLFOX (11.4 months, 95% CI, 9.1-21.0) versus ToGA regimens (7.5, 6.4-8.5), p  We have updated the external validity of clinical trials with trastuzumab in first-line treatment of gastric cancer. Our data confirm the comparable outcomes of ToGA regimens and CAPOX-trastuzumab in clinical practice and point toward a possible benefit of FOLFOX-trastuzumab, contingent on the subtypes typically less sensitive to trastuzumab, to be confirmed in clinical trials.
SN 1758-8340
YR 2021
FD 2021-06-17
LK https://hdl.handle.net/10668/27514
UL https://hdl.handle.net/10668/27514
LA en
DS RISalud
RD Apr 11, 2025